Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nurix Therapeutics (NRIX) Receivables (2021 - 2025)

Nurix Therapeutics (NRIX) has disclosed Receivables for 5 consecutive years, with $20.7 million as the latest value for Q2 2025.

  • On a quarterly basis, Receivables changed N/A to $20.7 million in Q2 2025 year-over-year; TTM through May 2025 was $20.7 million, a N/A change, with the full-year FY2024 number at $1.5 million, changed N/A from a year prior.
  • Receivables was $20.7 million for Q2 2025 at Nurix Therapeutics, up from $1.5 million in the prior quarter.
  • In the past five years, Receivables ranged from a high of $20.7 million in Q2 2025 to a low of $1.0 million in Q4 2022.
  • A 5-year average of $6.9 million and a median of $6.9 million in 2021 define the central range for Receivables.
  • Biggest YoY gain for Receivables was 85.51% in 2022; the steepest drop was 85.51% in 2022.
  • Nurix Therapeutics' Receivables stood at $6.9 million in 2021, then crashed by 85.51% to $1.0 million in 2022, then skyrocketed by 700.0% to $8.0 million in 2023, then plummeted by 81.25% to $1.5 million in 2024, then surged by 1280.0% to $20.7 million in 2025.
  • Per Business Quant, the three most recent readings for NRIX's Receivables are $20.7 million (Q2 2025), $1.5 million (Q4 2024), and $8.0 million (Q3 2023).